ribaxamase + ceftriaxone

**ribaxamase + ceftriaxone** is a combination therapy consisting of **oral ribaxamase** (SYN-004), an orally administered β-lactamase enzyme, and **intravenous ceftriaxone**, a third-generation cephalosporin antibiotic. Ribaxamase is designed to degrade β-lactam antibiotics such as ceftriaxone that enter the gastrointestinal tract via biliary excretion after systemic administration. The goal is to protect the gut microbiome from disruption, thereby reducing the risk of antibiotic-associated complications such as *Clostridium difficile* infection and the emergence of antimicrobial resistance. The combination does not alter ceftriaxone’s systemic pharmacokinetics or efficacy but locally inactivates excreted antibiotic, preserving colonization resistance and microbiome integrity[1][3][4][6].

Brand names

Rocephin

Other names

ribaxamase + ceftriaxoneoral β-lactamase + intravenous ceftriaxone